BioNTech ends Phase 2 trial of autogene cevumeran in colorectal cancer
The company halted the BNT122-01 study after a safety board found an overall survival imbalance and said further follow-up would not change the efficacy outcome.
SEC filing
Latest
12 stories
Yesterday
Monday, September 28
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig, pumitamig in SCLC
Tuesday, September 15
BioNTech posts results for mpox vaccine BNT166a Phase I/II trial NCT05988203
Thursday, September 3
CIBINQO label updated by FDA; Pfizer's rimegepant China trial and pipeline items still active
Friday, August 28
BioNTech posts results for Phase I/IIa malaria RNA vaccine trial; CHMI portion skipped
Thursday, August 27
FDA approves updated Pfizer-BioNTech COVID-19 vaccine targeting XFG variant
The 2026-2027 formula gained approval for older adults and higher-risk younger people, with shipping starting immediately.
SEC filing
Friday, August 21
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studies
Tuesday, August 11
Genmab terminates Phase 1/2 GEN1055 trial for strategic reasons; results now posted
Tuesday, August 4
BioNTech names Guido Oelkers CEO, trims 2026 revenue guidance in Q2 update
The company reported a wider net loss and cut its full-year revenue outlook to €1.6–1.9 billion while confirming Oelkers will succeed Ugur Sahin by February 2027.
SEC filing (2)